IFIT3 and breast carcinoma: Accordingly, high IFIT1 and IFIT3 expression have been correlated with a better therapeutic response to IFNs along with chemotherapeutics and immunostimulating agents in patients with breast cancer, glioblastoma, and hepatocellular carcinoma (Zhang et al., 2016; Yang et al., 2017; Nushtaeva et al., 2018).